Is Zohydro ER Still Available? Risks, Withdrawal, and Treatment

Zohydro ER, an extended-release capsule containing pure hydrocodone, was approved by the FDA in 2013 and became one of the most controversial opioid painkillers on the market. According to recent reports, the brand name has since been discontinued in the US, though the drug’s risks, and the risks of hydrocodone dependence generally, remain relevant for anyone who was prescribed it or is researching it now. This guide covers what Zohydro ER was, why it drew controversy, what withdrawal looks like, and where to turn for treatment.

Zohydro ER was an FDA-approved extended-release hydrocodone capsule, notable for containing no acetaminophen, unlike combination opioids such as Vicodin. Reports indicate the brand has been discontinued in the US since 2022, though hydrocodone dependence and withdrawal remain relevant for anyone previously prescribed it. Withdrawal symptoms typically begin 6 to 12 hours after the last dose, peak around 48 to 72 hours, and largely resolve within 5 to 7 days, though cravings can persist longer.

What Was Zohydro ER?

Zohydro ER was an FDA-approved extended-release capsule containing pure hydrocodone bitartrate, approved in 2013 for severe, around-the-clock pain requiring long-term opioid treatment. Unlike combination products such as Vicodin or Norco, it contained no acetaminophen, which removed a natural deterrent to dose escalation. According to recent reports, the brand has been discontinued in the US since 2022. If you were previously prescribed Zohydro ER, the hydrocodone dependence it can cause, and the withdrawal process, remain the same regardless of whether the specific brand is still on shelves.

Why Zohydro ER Was Controversial

Zohydro ER’s 2013 approval happened over the objection of the FDA’s own advisory committee, which had recommended against approval months earlier, citing insufficient evidence that benefits outweighed the risks. The agency’s reversal drew sharp criticism from addiction medicine specialists and public health advocates. Dr. Andrew Kolodny, then with Physicians for Responsible Opioid Prescribing, warned that a high-dose, single-entity hydrocodone product without abuse-deterrent features could worsen patterns already seen with other extended-release opioids.

The core concern was straightforward: Zohydro ER capsules contained 10 to 50mg of hydrocodone, several times more than the 2.5 to 10mg found in typical combination tablets, with no acetaminophen to limit how much someone could take. If the capsule was crushed, chewed, or dissolved, the entire extended-release dose could be absorbed at once, a phenomenon known as dose dumping, turning a 12-hour dose into an immediate, high-concentration exposure.

The controversy also arrived at a specific moment: approval preceded the DEA’s 2014 decision to reschedule hydrocodone combination products from Schedule III to Schedule II, tightening prescribing rules. Critics argued Zohydro ER’s approval created a window of looser oversight right before that shift took effect.

Manufacturer Zogenix defended the approval, pointing to a Risk Evaluation and Mitigation Strategy and arguing the drug could reduce acetaminophen-related liver injury for patients who needed a pure hydrocodone option. Public health advocates remained unconvinced that these measures were sufficient given the scale of the opioid crisis already underway at the time.

The disagreement wasn’t really about whether hydrocodone itself was dangerous; every party involved agreed it was. It was about whether a formulation removing one of the few practical barriers to misuse belonged on the market at that specific moment, with that specific level of oversight. That framing is worth keeping in mind, since the same tension resurfaces with most new high-potency opioid formulations.

What Happened to Zohydro ER?

According to recent reports, the Zohydro ER brand name has been discontinued in the US since 2022. This isn’t unusual for extended-release opioid products from this era; several similar formulations faced declining prescriptions as opioid stewardship guidelines tightened and safer alternatives became more widely used.

If you were previously prescribed Zohydro ER and still have doses on hand, the safest approach is disposal through an official take-back program rather than continued use of an unmonitored supply, along with a conversation with a prescriber about pain management going forward. If you’re researching Zohydro ER because someone in your life used it, the risks described in this guide, dependence, withdrawal, and overdose risk from hydrocodone, still apply, whether the specific brand is currently available or not.

This kind of situation, researching a medication that turns out to no longer be on the market, is more common than people expect. Pharmaceutical companies discontinue specific brand names for business reasons that have little to do with the underlying drug’s safety profile, while the active ingredient often remains available under other formulations or generic names. Confirming current availability with a pharmacist or prescriber is always more reliable than assuming based on what a search result from several years ago suggests.

Signs of Hydrocodone Dependence and Addiction

Recognizing opioid use disorder early improves outcomes. Behavioral signs include taking larger doses or using for longer than intended, a persistent desire or repeated unsuccessful attempts to cut back, spending significant time obtaining or recovering from use, and continuing use despite it causing problems at work, in relationships, or with health.

Physical signs can include constricted pupils, sedation, slurred speech, and withdrawal symptoms appearing between doses. Family members often notice mood swings, secrecy around medication, or unexplained financial strain before the person themselves is willing to acknowledge a problem.

Addiction can develop even in people taking a medication exactly as prescribed. This isn’t a matter of willpower or character; it’s a predictable risk of how opioids interact with the brain’s reward system over time, and it’s treatable.

Clinicians often use validated screening tools rather than relying on visible severity alone, since dependence can develop gradually enough that neither the person using the medication nor their family notices the shift until it’s fairly advanced. Framing this as a medical condition rather than a personal failing tends to make people more willing to raise concerns early, when intervention is easier, rather than waiting until consequences force the issue.

Withdrawal Timeline and What to Expect

Hydrocodone withdrawal typically begins 6 to 12 hours after the last dose of an extended-release formulation, with symptoms peaking around 48 to 72 hours and largely resolving over 5 to 7 days, though psychological cravings can last longer.

Common symptoms include watery eyes, runny nose, yawning, sweating, restlessness, insomnia, abdominal cramping, nausea, vomiting, diarrhea, and muscle aches. These symptoms are rarely life-threatening on their own, but they’re severe enough that unsupervised attempts to stop frequently end in relapse, often at a point when tolerance has already dropped and overdose risk is higher than before.

Tapering under medical supervision, typically reducing the dose by 10 to 25 percent every one to two weeks, can meaningfully reduce withdrawal severity compared to stopping abruptly.

For opioid use disorder specifically, withdrawal management alone tends to have a high relapse rate without follow-up support. Medications such as buprenorphine or methadone are commonly used as part of ongoing treatment, alongside counselling and behavioral therapy, rather than treating detox as the endpoint of care. Relapse after unsupervised detox carries particular risk with any opioid, since reduced tolerance following a period of abstinence can make a previously familiar dose fatal.

Frequently Asked Questions

Is Zohydro ER Still Prescribed?

According to recent reports, the Zohydro ER brand has been discontinued in the US since 2022. Hydrocodone itself, in other formulations, remains available by prescription, and the dependence and withdrawal risks discussed in this guide apply to hydrocodone generally, not just this specific brand.

What Should I Do With Leftover Zohydro ER?

Dispose of it through an official medication take-back program rather than keeping it or using it without current medical supervision. Continuing to use an unmonitored, discontinued prescription carries real risk, particularly around dosing accuracy over time.

Can Naloxone Reverse a Hydrocodone Overdose?

Yes. Naloxone can reverse hydrocodone overdose, though hydrocodone’s duration of action may outlast naloxone’s effects, sometimes requiring repeated doses under medical supervision. Anyone around active opioid use should have access to naloxone and know the signs of overdose: slow or absent breathing, pinpoint pupils, and unresponsiveness.

Why Was Zohydro ER Controversial When It Was Approved?

It was the first single-entity hydrocodone product without acetaminophen, which removed a natural limit on dose escalation. The FDA approved it despite its own advisory committee recommending against approval, drawing criticism from addiction specialists concerned it would worsen an already serious opioid crisis.